Singapore (VNA) - Pharmaceutical giant GlaxoSmithKline (GSK) of the UK unveilednew, fully automated continuous manufacturing facilities worth a total of 130million SGD (95.61 million USD) in Singapore on July 5.
Speakingat the launch ceremony, Minister of Trade and Industry of Singapore Chan ChunSing affirmed that the cooperation between the Singaporean government,companies and workers help Singapore maintain its position as the globalbiomedical centre producing high quality pharmaceutical products.
RegisSimard, President Pharmaceuticals Supply Chain of the GSK, said as one of themost innovative cities in the world, Singapore is home to an ecosystem ofcompanies and organisations that are creating and exporting innovativesolutions.
Innovationis at the heart of GSK, the company is glad to invest in scientific andtechnical excellence in Singapore to develop and launch the next generation ofproducts which meet the needs of patients, payers and consumers, he added.
Theinvestment behind the new facilities is part of the 10-year SingaporeManufacturing Roadmap of the GSK and the Singapore Economic Development Board.
Theinvestment demonstrates GSK's commitment to Singapore as a key manufacturingand supply site for GSK's global pharmaceutical business and a testbed foradvanced manufacturing technology.
The firstNew Chemical Entity (NCE) to be developed at the new facility will be a neworal treatment for anaemia associated with chronic kidney disease.
Theexpansion of the production building will strengthen GSK's capability toproduce Dolutegravir, a key GSK asset for HIV treatment.-VNA